• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

FDA Clears Image Processing Software with Emphasis on Nuclear Medicine Imaging Workflow

Article

The InterView Fusion and InterView XP reportedly improve image quality for single-photon emission computed tomography (SPECT) and offer imaging tools specifically geared to common nuclear medicine studies ranging from bone imaging to cardiac assessment and lung imaging.

Specifically tailored to workflows for nuclear medicine and molecular imaging, the InterView™ Fusion (Mediso) and InterView XP (Mediso) multimodality (PET/SPECT/MRI/CT) image processing and reporting software have garnered 510(k) clearance from the Food and Drug Administration (FDA).

In addition to bolstering image quality for single-photon emission computed tomography (SPECT) with iterative reconstruction, the InterView software offers specialized tools for a variety of common nuclear medicine studies including cardiac, bone, thyroid, liver, and lung imaging, according to Mediso.

The company said the InterView software also features a variety of modules that facilitate automated lesion detection and segmentation as well as image denoising.

FDA Clears Image Processing Software with Emphasis on Nuclear Medicine Imaging Workflow

In addition to bolstering image quality for single-photon emission computed tomography (SPECT) with iterative reconstruction, the InterView software offers specialized tools for a variety of common nuclear medicine studies including bone imaging. (Images courtesy of Mediso.)

Mediso added that the vendor independent software can be utilized on stand-alone workstations or be incorporated seamlessly into physical or virtual servers of hospital information systems.

“The InterView software together with the AnyScan SPECT and SPECT/CT clinical systems provide a complete solution for all nuclear medicine routine and research application, and they demonstrate our continuous commitment to the molecular imaging market,” noted Istvan Bagamery, the founder and CEO of Mediso.

Recent Videos
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Nina Kottler, MD, MS
Related Content
© 2024 MJH Life Sciences

All rights reserved.